pelabresib in myelofibrosis: the manifest trials
Published 1 year ago • 319 plays • Length 1:34Download video MP4
Download video MP3
Similar videos
-
3:38
manifest: pelabresib in combination with ruxolitinib in myelofibrosis
-
3:56
an update on manifest: pelabresib monotherapy or as add-on to ruxolitinib in myelofibrosis
-
3:49
manifest: pelabresib (cpi-0610) ruxolitinib in advanced myelofibrosis patients
-
1:38
pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
-
5:12
ongoing clinical trials of ruxolitinib-based combinations in myelofibrosis
-
49:52
primary myelofibrosis
-
59:37
shaping modern management of myelofibrosis
-
14:40
primary myelofibrosis (pmf)
-
3:43
updated results from manifest arm 2: pelabresib as add-on to ruxolitinib in myelofibrosis
-
3:21
manifest: ruxolitinib plus pelabresib for jak-inhibitor naïve myelofibrosis
-
1:30
results of the ruxopeg trial: combining ruxolitinib and interferon in patients with myelofibrosis
-
3:06
manifest study of pelabresib (cpi-0610) in myelofibrosis
-
3:33
manifest: pelabresib (cpi-0610) shows promise in myelofibrosis
-
2:57
preliminary data from the manifest study: pelabresib in combination with ruxolitinib in mf
-
1:00
the promising role of pelabresib in the treatment of mf
-
2:41
benefits of pelabresib with ruxolitinib for treatment naïve myelofibrosis
-
2:21
recent updates on pelabresib for myelofibrosis
-
1:55
the promise of pelabresib in mf and insights into the manifest-2 study
-
2:10
manifest update: pelabresib clinical and pathological investigations
-
3:55
manifest: pelabresib updates
-
2:08
pelabresib (cpi-0610): a novel bet inhibitor for mf